secwatch / observer
8-K filed November 16, 2023, 6:59 PM ET ticker XAGE CIK 0001842939
leadership confidence high sentiment neutral materiality 0.30

Carmell appoints Scott Frisch (AARP COO/CFO) and Gilles Spenlehauer as independent directors

Longevity Health Holdings, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gilles Spenlehauer

Director
XAGE · Longevity Health Holdings, Inc.
Effective
2023-11-15
Filed
November 16, 2023, 6:59 PM ET
the Board appointed Scott Frisch and Gilles Spenlehauer (collectively, the “New Directors”) to serve as directors on the Board of the Company.
Appointed

Scott Frisch

Director
XAGE · Longevity Health Holdings, Inc.
Effective
2023-11-15
Filed
November 16, 2023, 6:59 PM ET
the Board appointed Scott Frisch and Gilles Spenlehauer (collectively, the “New Directors”) to serve as directors on the Board of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gilles Spenlehauer was appointed as Director at Longevity Health Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
the Board appointed Scott Frisch and Gilles Spenlehauer (collectively, the “New Directors”) to serve as directors on the Board of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Frisch was appointed as Director at Longevity Health Holdings, Inc..

Action
appointed
Role
Director
Exact text from the filing
the Board appointed Scott Frisch and Gilles Spenlehauer (collectively, the “New Directors”) to serve as directors on the Board of the Company.
View on SEC.gov

Longevity Health Holdings, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-278158
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.